B[ACKGROUND]{.smallcaps} {#sec1-1}
========================

An important issue in biomarker research is the intra- and inter-tumor heterogeneity of the composition of tumors.\[[@ref1][@ref2]\] Tumors arise and grow in a very complex environment of different cell types, including primary tumor cells, stromal cells, and immune cells, among others. All of these different cell populations contribute to varying degrees to any protein, DNA, or RNA signal obtained as a result of studies working on patient material. This heterogeneity has been proposed as a significant challenge to successful cancer biomarker research.\[[@ref3]\] Consequently, multiple authors have demonstrated the importance of enrichment to obtain specific signals for unbiased biomarker discovery.\[[@ref4][@ref5][@ref6]\]

The lack of biomarkers remains an urgent issue in colorectal cancer. To this day, the tumor node metastasis (TNM) staging system remains the "gold standard" for tumor classification in this disease, which assigns patients into one of four categories with unique treatment regimens. The lack of biomarkers is most prominent in Stage 2 and 3 patients. While Stage 2 patients are usually surgically treated, Stage 3 patients are readily administered adjuvant therapies. These differences in treatment regimen are based predominantly on the absence or presence, respectively, of lymph node metastases. The need for additional biomarkers for improved patient stratification and management is found in the conflicting finding that subgroups of Stage 3 patients (Stage 3A) are characterized by more favorable prognosis than subgroups of Stage 2 patients (Stage 2B and 2C).

Among the available methods for biomarker discovery, mass spectrometry (MS) certainly ranks among the methods with the highest accuracy and throughput. The typical application for mass spectrometry in protein biomarkers discovery refers to an untargeted, or "shotgun," approach. This procedure involves extraction and denaturation of proteins from frozen or formalin-fixed paraffin-embedded (FFPE) tissue into solution, followed by enzymatic digestion with specific proteases such as trypsin. The resulting peptide solution is chromatographically separated, ionized, and injected for analysis into an MS instrument in an approach known as liquid chromatography-based MS \[LC-MS\]. Because of the principle of injecting a solution of fragmented proteins into an MS instrument, this approach has also been coined "shotgun proteomics."

MS represents a well-suited method for biomarker discovery, but additional methods are required for the subsequent validation of identified candidates. In that respect, the combination of digital image analysis (DIA) and immunohistochemistry (IHC) has recently shown very promising results. For example, the Ki67 marker has been used for years as a proliferative marker in breast cancer but is limited by significant interobserver variability. Recently, however, Stålhammar *et al*.\[[@ref7]\] have used DIA for more reliable and objective scoring for Ki67. The potential of DIA can be further increased in combination with a next-generation tissue microarray^®^ (ngTMA) approach that allows for targeted regions of tissue to be included in digital analysis.\[[@ref8][@ref9][@ref10]\]

The aim of this study is the discovery of novel potential biomarkers for patients with Stage 2 colorectal cancer. This aim is achieved by developing a pipeline for biomarker discovery that begins by enriching tumor samples for MS analysis using ngTMA technology, followed by validation of candidate proteins using quantitative DIA. This combination of methodologies represents a new milestone for the identification and validation of biomarkers in cancer research.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Patients {#sec2-1}
--------

A total of 413 surgically treated patients with primary colorectal cancer were entered into this study. Patients were treated at the University Hospital of Bern between 2002 and 2013. Patient characteristics are found in [Supplementary Table 1](#T1){ref-type="table"}. All diagnostic slides were re-reviewed by expert gastrointestinal pathologists, and the following histopathological information was recorded: tumor grade, lymphatic and venous invasion, pathological T, N, and M stage, overall TNM stage, perineural invasion, tumor border configuration, tumor budding score assessed according to the ITBCC guidelines,\[[@ref11]\] microsatellite status, and tumor histology. Clinical data included age at diagnosis, gender, survival time, and therapy. No cases were preoperatively treated. Median overall survival time for the full cohort was 42.7 months.

###### 

Clinical-pathological features of the patient cohort

  Feature                                                                       Frequency (%)
  ----------------------------------------------------------------------------- ------------------
  Age (median) (minimum-maximum)                                                70.6 (19.1-92.1)
  Sex                                                                           
   Female                                                                       161 (39.2)
   Male                                                                         250 (60.8)
  Grade                                                                         
   1                                                                            10 (2.9)
   2                                                                            262 (75.3)
   3                                                                            76 (21.8)
  L                                                                             
   0                                                                            126 (34.7)
   1                                                                            237 (65.3)
  V                                                                             
   0                                                                            168 (45.8)
   1                                                                            199 (54.2)
  pT                                                                            
   0                                                                            22 (5.7)
   1                                                                            9 (2.3)
   2                                                                            66 (17.0)
   3                                                                            210 (54.0)
   4                                                                            82 (21.0)
  pN                                                                            
   0                                                                            199 (48.5)
   1                                                                            124 (30.2)
   2                                                                            87 (21.2)
  pM                                                                            
   0                                                                            296 (72.0)
   1                                                                            115 (28.0)
  TNM stage                                                                     
   0                                                                            19 (4.6)
   1                                                                            47 (11.4)
   2                                                                            106 (25.8)
   3                                                                            124 (30.2)
   4                                                                            115 (28.0)
  Pn                                                                            
   0                                                                            281 (78.7)
   1                                                                            76 (21.3)
  Preoperative TX                                                               
   No                                                                           360 (87.6)
   Yes                                                                          51 (12.4)
  Tumor border configuration (percentage expanding, median) (minimum-maximum)   50 (0-100)
  Budding (ITBCC, median) (minimum-maximum)                                     3 (0-195)
  Microsatellite status                                                         
   MSI                                                                          30 (14.7)
   MSS                                                                          174 (85.3)
  Tumor histology                                                               
   Adenocarcinoma                                                               335 (87.5)
   Mucinous                                                                     32 (8.4)
   Other                                                                        16 (4.2)
  Overall survival (median) (minimum-maximum)                                   42.7 (0-182.9)
  Disease-free survival (median) (minimum-maximum)                              38.8 (0-161.5)

TNM: Tumor, node, metastasis, MSI: Microsatellite instability, MSS: Microsatellite stable

Next-generation tissue microarray construction {#sec2-2}
----------------------------------------------

Blocks were retrieved from the archives of the Institute of Pathology, University of Bern, Switzerland. From each block, an H and E slide was created and scanned (digitalized) on a Panoramic 250 scanner (3DHistech, Budapest, Hungary). On each digital slide created this way, multiple circular digital annotations (i.e., regions of interest \[ROI\]) with a diameter of 0.6 and 1.0 mm were annotated in histological tumor regions of all patients in the cohort. Digital slides were aligned with their corresponding blocks, and annotated regions were extracted from the block and placed in a new, empty paraffin block. This resulted in ngTMA^®^ featuring multiple cores per patient in the validation cohort \[Supplementary Figure 1\]. The validation cohort ngTMA^®^ contained in a total of 796 cores. The use of clinical data and tissue samples was approved by the Ethics Committee of the Canton of Bern (KEK 2014/200).

Protein extraction and mass spectrometry {#sec2-3}
----------------------------------------

From these 413 patients, 26 Stage 2 and 26 Stage 3 cases were selected for MS. Patients were selected to represent a balanced cohort without missing data for any feature including survival. Using the same technology as described above for TMAs, digital annotations were used to target regions of tumor epithelium. Blocks were aligned with the digital scans, and four cores from each patient were collected in 2 ml tubes. Extracted cores were re-embedded in a 7 mm × 7 mm paraffin block, 20 sections (15 μm each) from each block were cut, and protein was extracted according to the "Extraction of Total Protein from FFPE Tissue Sections" protocol of the Qproteome^®^ FFPE Tissue Handbook (p. 18-19, Qiagen). 15 μl of the resulting protein extract was injected on an LC-MS/MS system (EASY nLC1000 liquid chromatograph coupled to a QExactive mass spectrometer, both from ThermoFisher Scientific). To reinforce the confidence in identified biomarkers, MS results were evaluated with one commercial (Proteome Discoverer version 2.2, ThermoFisher) and one freely available (MaxQuant version 1.5.8.3) software with the following settings: up to two missed cleavages in tryptic digest peptides, carbamidomethylation on cysteine as fixed modification and N-terminal acetylation and methionine oxidation as variable modifications. A mass tolerance of 10 ppm was used for precursor ions and 20 ppm for fragment ions. False discovery rate on protein level was set to 0.01 (1%), with a minimum of two unique peptides required for protein identification.

After result evaluation, a python script was specifically developed to extract intensities of all identified proteins from both software packages by summing up individual intensities of the three most abundant peptide ions. This approach is known as "Top 3" and has been previously shown to be the most accurate approximation of abundance in label-free protein quantification.\[[@ref12][@ref13]\] MaxQuant-calculated "label-free quantification" (LFQ) scores were also included in the statistical evaluation. The three calculated quantification methods (LFQ and Top 3 scores from MaxQuant, Top 3 score from Proteome Discoverer) were imported into R version 3.4.2\[[@ref14]\] and were used for calculating fold change and associated *P* values for all proteins identified with at least two unique peptides. All proteins exhibiting significant (*P* \< 0.05) fold changes in all three scores were considered as true biomarkers. The cathepsin B protein was selected for subsequent validation on the previously constructed ngTMA^®^ cohort.

Immunohistochemistry {#sec2-4}
--------------------

For IHC validation, two sequential slides of the validation ngTMA^®^ were created and stained with cytokeratin (clone AE1/AE3, Cell Signaling) and cathepsin B (clone EPR4323, GeneTex), respectively, on the automated BOND RX^®^ (Leica Biosystems, Newcastle, UK). Digital copies of slides were obtained at highest quality settings and ×40 resolution on a Panoramic 250 Scanner and stored on our institute servers. The intensity of cathepsin B was visually assessed and classified into one of two "visual intensity" categories, namely category 0 (low expression) or category 1 (high expression) based on reference intensities. These visual intensity categories were also combined with clinical, pathological data for inclusion in the statistical analysis.

Digital image analysis using QuPath {#sec2-5}
-----------------------------------

For quantification with DIA, slides were imported into the QuPath software version 0.1.2,\[[@ref15]\] core areas were detected using the built-in TMA dearrayer module, and the position of tissue cores was manually adjusted to ensure proper recognition and further processing of all cores on the slide. All cytokeratin-stained tissue cores were then evaluated for inclusion or exclusion in further data analysis. Tissue cores were excluded from analysis if (i) their shape was distorted such that the tissue region extended beyond the borders of the 0.85 mm circular annotation, (ii) they contained any amount of normal epithelial tissue, (iii) they showed clear indications that the staining protocol did not work, (iv) they contained overlapping tissue, or (v) they contained \< 25% of tissue. Cores for which observers were not in agreement were discussed after evaluation until agreement of both evaluators was reached.

To all tissue cores included in the analysis, QuPath\'s simple linear iterative clustering superpixel segmentation (Gaussian sigma: 5 μm, superpixel spacing: 10 μm, iterations: 15, regularization: 0.1) was applied. This approach is very well suited for capturing the histological shape of tissue cores. QuPath intensity features (preferred pixel size: 2 μm, region: ROI, tile diameter: 25 μm, compute all features including Haralick features \[Haralick *et al*., 1973\] with 32 bins) were calculated for all superpixels identified this way.

After calculation, annotations were placed on randomly chosen tissue cores of each cytokeratin slide in three regions: epithelium, stroma, and whitespace. It was ensured that each annotation contained 3000 (±5%) superpixels. Annotated superpixels were used to build a Random Trees detection classifier for the entire TMA slide, and this approach ensured a balanced training set in the three selected regions. Superpixels belonging to the same class were then combined to a single annotation, resulting in three annotations (epithelium, stroma, and whitespace) on each tissue core of all slides.

After classification of superpixels, epithelial regions were manually transferred to corresponding cores of the sequential ngTMA^®^ slide stained for cathepsin B. Corresponding cores were aligned, the epithelial annotation from the cytokeratin slide was manually transferred to the cathepsin B slide, and necrotic areas as well as intraglandular debris of the transferred annotation were manually removed before further analysis. Annotations were not transferred if the core on the cathepsin B slide (i) showed clear indications that the staining did not work, (ii) contained overlapping tissue, (iii) was distorted in a way that the core tissue region extended beyond the borders of the 0.85 mm circular annotation, or (iv) contained \< 25% of tissue. Upon successful transfer of all epithelial annotations to the candidate biomarker slide, the watershed cell detection method (detection image: optical density sum, requested pixel size: 0.5 μm, background radius: 8 μm, median filter radius: 0 μm, Sigma: 1.5 μm, minimum area: 10 μm^2^, maximum area: 400 μm^2^, threshold: 0.1, checked options: splitting by shape, include cell nucleus, smooth boundaries) was applied to all annotations on the candidate biomarker slide. Cell features were calculated for all cells using QuPath\'s add intensity features option (preferred pixel size: 0.5 μm, region: ROI, tile diameter: 25 μm, compute all features including Haralick features with 32 bins). This approach calculates 163 parameters for each detected cell on the candidate biomarker slide, which were exported into a tab-delimited file using a QuPath script specifically developed for this purpose. Exported measurements from all cells on the biomarker candidate slide were combined with relevant clinical pathological features and imported into R version 3.4.2 for statistical analysis.

Study design {#sec2-6}
------------

Patients for biomarker discovery (26 patients from Stage 2 and 3, respectively) as well as for the construction of the validation cohort were chosen from an initial four hundred and thirteen CRC patients. The complete study design is shown in [Figure 1](#F1){ref-type="fig"}.

![Workflow for digital pathology (left) and mass spectrometry (right) analysis in the presented study](JPI-10-40-g001){#F1}

Statistical analysis {#sec2-7}
--------------------

All statistical analysis was performed in R version 3.4.2. Differences in survival curves were assessed using the log-rank test. Biomarkers in the three scoring approaches were identified using the *t*- test. Only proteins with *P* \< 0.05 in all three comparisons were considered significant. The association of visual intensity categories and Brightness_Max with clinical-pathological features was performed using the Spearman correlation coefficient, Chi-square, or Wilcoxon\'s rank-sum test.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Differentially expressed proteins between Stage 2 and 3 patients {#sec2-8}
----------------------------------------------------------------

Differential protein expression between Stage 2 and 3 patients revealed 1947 proteins identified with at least two unique peptides. The three types of quantification scores (LFQ scores from MaxQuant and Top 3 scores from MaxQuant and Proteome Discoverer) were combined using a python script developed specifically for this purpose and analyzed in R. To reinforce the validity of biomarker candidates, only proteins with a significant *P* value (*P* \< 0.05) fold change in all three scores were considered as true biomarkers \[[Figure 2a](#F2){ref-type="fig"}\]. This resulted in eight candidates for subsequent validation \[[Figure 2b](#F2){ref-type="fig"}\]. Based on the body of available literature, the cathepsin B protein was chosen for further validation on the validation cohort using DIA.

![(a) *P* values and associated fold change between Stage 2 and Stage 3 patients for all proteins identified in our mass spectrometry results for each of the three quantification scores (◊: "Top3" scores from ProteomeDiscoverer, ○: label-free quantification scores from MaxQuant, +: "Top 3" scores from MaxQuant). Note that a negative fold change indicates higher expression in Stage 2. Eight proteins with *P* \< 0.05 in all three quantification scores (indicated in bold) were considered as biomarker candidates. (b) Additional information for each of the eight biomarker candidates](JPI-10-40-g002){#F2}

Assessment of cathepsin B by visual assessment of next-generation tissue microarray {#sec2-9}
-----------------------------------------------------------------------------------

In a first step, the expression of cathepsin B in all patients in the validation cohort was visually assessed and assigned one of two categories "low/no cathepsin B expression" or "high cathepsin B expression" based on reference images \[[Figure 3](#F3){ref-type="fig"}\]. All patients in the cohort were then stratified for overall survival by this visual intensity category \[[Figure 4a](#F4){ref-type="fig"}\]. However, these results did not indicate any significant stratification of patients (log-rank test, *P* \> 0.05). In addition, this categorization into expression categories did not reveal any significant associations with clinical-pathological features \[[Table 1](#T2){ref-type="table"}\]. Based on these findings, subgroup analysis for available Stage 2 patients was performed. Stratification of Stage 2 patients by visual intensity is shown in [Figure 4b](#F4){ref-type="fig"}. Although not statistically significant, a trend in the stratification of patients can be observed.

![Reference tissue cores stained for cathepsin B used for assessment of visual intensity. The top row showing cores which were categorized as "low cathepsin B expression," the bottom row showing cores categorized as "high cathepsin B expression"](JPI-10-40-g003){#F3}

![Overall survival in the full validation cohort (a) and in Stage 2 patients of the validation cohort (b), stratified by visual intensity category. Indicated *P* values are the result of a log-rank test](JPI-10-40-g004){#F4}

###### 

Association of cathepsin B staining by visual assessment and digital image analysis and clinicopathological features

  Clinical-pathological variable   Visual intensity (*P*)   Brightness_Max in Stage 2 (*P*)   Brightness_Max in full cohort (*P*)
  -------------------------------- ------------------------ --------------------------------- -------------------------------------
  Age                              0.960                    0.089                             0.747
  Gender                           0.296                    0.517                             0.341
  Tumor histology                  0.338                    0.797                             0.488
  Tumor location                   0.392                    0.030                             0.583
  pT                               0.917                    0.143                             \<0.001
  pN                               0.831                    \-                                0.004
  cM                               1.000                    \-                                0.001
  TNM stage                        0.831                    \-                                \<0.001
  Grade                            0.511                    0.343                             0.001
  L                                1.000                    0.089                             \<0.001
  V                                0.321                    0.650                             0.008
  Pn                               0.430                    0.296                             \<0.001
  Number of buds (ITBCC)           1.000                    0.042                             0.007
  Budding category                 0.833                    0.086                             0.042
  Tumor border configuration       0.615                    0.117                             0.001
  MMR status                       1.000                    0.090                             0.024
  Overall survival                 0.612                    0.044                             0.042

TNM: Tumor, node, metastasis

Digital image analysis of cathepsin B {#sec2-10}
-------------------------------------

Our categorization of cathepsin B by visual assessment did not reveal any significant stratification of patients. However, we hypothesized that DIA, which allows analysis of IHC expression on a continuous rather than a categorical scale, would improve the associations with clinical-pathological features and potentially yield a "digital" surrogate for the expression of cathepsin B. Therefore, to identify which of the measured QuPath variables would most closely represent the visually assessed intensity, each variable was independently analyzed in a Cox proportional hazards model containing Stage 2 patients in the validation cohort. The limited size of the cohort precluded the application of a multivariate model. Univariate Cox analysis resulted in three QuPath variables with significant (*P* \< 0.05) hazard ratios: Red_Max, Residual_Min, and Brightness_Max. We considered Brightness_Max, which is representative of the maximum median pixel intensity of all cells detected on particular patient core in the tumor epithelium region, as the best surrogate for visual intensity. Since visual intensity is manifested by higher staining intensity (i.e., darker staining), we had an *a priori* expectation that Brightness_Max would be inversely correlated with visual intensity. Indeed, our data showed significantly higher values of Brightness_Max values in the "low cathepsin B expression" category, which confirmed our a priori hypothesis \[Supplementary Figure 2\].

Association of cathepsin B Brightness_Max scores with clinical pathological features {#sec2-11}
------------------------------------------------------------------------------------

Our DIA approach incorporated the alignment of cytokeratin-stained and cathepsin B-stained cores, followed by cell detection and digital assessment of staining intensity. Based on the specificity of cytokeratin to epithelial regions, this approach ensured that cathepsin B expression would be digitally assessed only in the tumor epithelial regions, thereby removing any potential bias from stromal signals \[[Figure 5](#F5){ref-type="fig"}\]. Based on our DIA data, we successfully established QuPath\'s Brightness_Max measure as a digital surrogate of visual intensity. It also enabled an investigation of the association with important clinical pathological features of the validation cohort. This analysis was performed for both Stage 2 patients and for all patients in the validation cohort \[[Table 1](#T2){ref-type="table"}\]. Interestingly, we found lower values of Brightness_Max (i.e., higher expression of cathepsin B) significantly associated with less aggressive pathological features of CRC in the full cohort, such as the absence of lymphatic (*P* \< 0.001) and perineural (*P* \< 0.001) invasion, and a lower number of tumor buds (*P* = 0.007). We could also demonstrate a significant association of Brightness_Max with overall survival in the full cohort (*P* \< 0.05), although this was only found in univariate analysis. Unfortunately, Brightness_Max does not represent an independent prognostic factor in multivariate analysis when adjusting for other confounders.

![Digital image analysis workflow](JPI-10-40-g005){#F5}

C[ONCLUSIONS]{.smallcaps} {#sec1-4}
=========================

The lack of prognostic and predictive biomarkers remains an important issue in proper patient classification and management for CRC. In this study, we investigated whether the introduction of a novel approach coupling DIA and state-of-the-art tissue enrichment methodology to mass spectrometry for biomarker discovery would allow for the identification of clinically relevant novel biomarkers, with a particular focus on markers in Stage 2 patients. The presented study identified the human cysteine cathepsin B as a promising biomarker and proposed validation guidelines using ngTMA^®^ coupled to DIA on a previously established validation cohort of 413 patients. Although the cathepsin B protein is not as interesting in terms of differential protein expression compared to other candidates such as Hexokinase 3, it was chosen for validation based on a number of different reasons. First, the role of cathepsin B in cancer malignancy and progression is supported by a large body of literature: cathepsin B expression has been directly associated with a more aggressive phenotype and positive expression in tumor buds in CRC,\[[@ref16]\] and the cathepsin family of proteins is generally attributed an important promoting role in a multitude of cancers.\[[@ref17][@ref18][@ref19][@ref20]\] Second, the investigation of tumor budding as the main focus of our research group aligned well with the previously reported function of cathepsin B. Finally, the availability of a commercial antibody for cathepsin B and its excellent quality of staining was an inevitable prerequisite for validation in our study. Taken together, this renders cathepsin B the most obvious choice for validation in our list of biomarker candidates.

While our results indicated that the visually inspected cathepsin B category was not a suitable prognostic factor on the validation cohort, the analysis specific to Stage 2 patients revealed its prognostic potential. Stratification of patients by visual intensity category revealed two prognostic subgroups, with a trend toward statistical significance. Interestingly, the better prognostic subgroup is characterized by increased expression of cathepsin B, indicating a "protective" effect of this protein.

The role of cathepsin B, one of the eleven human cysteine cathepsins (B, C, F, H, L, K, O, S, V, W, X/Z), has been well described.\[[@ref21]\] The protein is constitutively expressed as a precursor on the rough endoplasmatic reticulum and transported to lysosomes, where it is converted into its active form. A dual role has been reported for this protein in cancer: On the one hand, it has been shown to promote tumor progression via increased secretion into the extracellular matrix and degradation of the basement membrane.\[[@ref22][@ref23][@ref24]\] On the other hand, cathepsin B has also been reported as an important proapoptotic component of apoptosis by cleaving anti-apoptotic members of the Bcl-2 family of proteins.\[[@ref25][@ref26]\] Taken together, evidence in the literature suggests opposing roles for cathepsin B in malignancy. Our data indicate that the "protective" effect of cathepsin B is more pronounced in our validation cohort since the favorable prognostic subgroup of Stage 2 patients is characterized by increased expression of cathepsin B.

With respect to DIA, our study revealed important points for consideration. We have proposed a method to successfully identify a digital "surrogate" measure based on the framework of visually assessed intensity levels. In this context, our approach outlines the benefits and challenges of incorporating DIA into biomarker discovery studies. On the one hand, DIA provides a continuous measure of visual intensity, which bears obvious benefits in terms of statistical evaluation compared to the classical categorical assessment of visual intensity. The benefits of a digital, continuous measure of intensity for biomarker validation are shown in [Table 1](#T2){ref-type="table"}, which outlines significant associations with relevant clinical pathological features in both Stage 2 patients and in all patients of the validation cohort. A comparison of the same features with categorical visual intensity fails to reach statistical significance.

On the other hand, our approach also outlines the challenges associated with DIA-based approaches. The amount of data produced by QuPath (and DIA software in general) is orders of magnitude larger than any type of visual assessment. This offers many more possibilities for data analysis, such as an examination of quantitative cell-specific expression data or cell--cell interactions. However, the resulting data analysis, processing, and storage are more challenging and require advanced expertise in bioinformatics, which may not be readily available in research institutions.

Our study may be limited in several aspects. One very important point is the mode of synthesis of cathepsin B. Proteins synthesized in the form of a precursor which is only activated at a later stage form a major challenge for IHC, since antibodies specific to either the precursor or its active form are difficult to obtain. In most cases, the IHC staining does not differentiate between the two forms, including the presented work. Therefore, our results cannot be used to distinguish whether the more favorable identified prognostic subgroup in Stage 2 is truly characterized by increased expression of cathepsin B, its precursor form, or a combination of the two. In addition, our experience has shown that while the incorporation of DIA approaches may increase the objectivity of results, image analysis software remains prone to imperfections. These imperfections may be manifested in the form of tissue artifacts, mast cells which intensely pick up a wide range of staining, or two closely adjacent cells which are falsely identified as one much larger cell. Such issues are avoided in visual assessment of staining intensities since they are "obvious" to the observer. This addresses an important aspect that will require further refinement in the comparison of visual versus digital pathology.

In conclusion, cathepsin B is a marker for more indolent tumor behavior and favorable prognosis in colorectal cancer. Our work has shown that inclusion of DIA increases objectivity compared to visual assessment. However, we have also outlined some of the challenges associated, including the amount and analysis of validation data. We estimate that with increasing popularity of various DIA software packages, this approach will be the focus of many future studies which will help to clarify current challenges in the comparison between visual and digital pathology.
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